Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro
- 23 August 2012
- journal article
- research article
- Published by Springer Nature in Archives of Toxicology
- Vol. 87 (2) , 361-370
Abstract
Mycophenolic acid (MPA) is an immunosuppressive agent that acts as a selective, non-reversible inhibitor of the enzyme inosine-5′-monophosphate dehydrogenase (IMPDH). Malformations have been described in children after maternal exposure to mycophenolate. However, the causal link is unclear in most cases because women had been treated with a combination of drugs and birth defects may have other causes. Therefore, it is important to study the action of this drug and its main metabolite on embryonic tissue. We studied the teratogenic potential of MPA and its major metabolite, the mycophenolic acid glucuronide (MPAG) in the rat whole-embryo culture. A total of 147 day 9.5 embryos were cultivated for 48 h in the standard medium containing 85 % serum. We tested MPA at concentrations of 0.1; 0.25; 0.5; 0.75 mg/l (0.31; 0.78; 1.56; 2.34 μM) and MPA glucuronide at concentrations of 3; 10; 30; 100 mg/l (6.04; 20.14; 60.43; 201.43 μM). Both substances are highly protein bound, and MPA glucuronide might displace MPA from protein binding. Therefore, we examined whether the effects of MPA can be enhanced when studied in combination with the glucuronide. Furthermore, the focus was on additional endpoints to the standard evaluation of cultivated embryos, such as development of cranial nerves [trigeminal nerve (V), facial nerve (VII), glossopharyngeal nerve (IX), vagus nerve (X)] after staining with an antibody against 2H3 neurofilament. Ultrastructural changes were evaluated by electron microscopy. At a concentration of 0.75 mg MPA/l medium, all embryos showed dysmorphic changes. Embryos exposed to 0.25 mg MPA/l medium showed impaired development of nerves, and at 0.1 mg/l, no effects were detectable. Concentration-dependent ultrastructural changes, such as signs of apoptosis, were found by electron microscopy. The examination of the metabolite in this assay showed that at a concentration of 100 mg MPAG/l, the embryos exhibited distinct malformations. This is probably caused by MPA, which was detectable at 0.6 % in the material used for our experiments. The combination of the parent compound (0.03; 0.1; 0.25 mg/l) with its metabolite MPAG (3 mg/l) did not cause enhanced toxicity under our experimental conditions. IMPDH, the target enzyme of MPA, could be detected in rat embryos on day 9.5 of embryonic development as well as at the end of the culture period 48 h later. In summary, MPA impairs embryonic development at low, therapeutically relevant concentrations, but the glucuronide does not exhibit such a potential. Activity of MPA is not enhanced by MPAG.Keywords
This publication has 23 references indexed in Scilit:
- An additional patient with mycophenolate mofetil embryopathy: Cardiac and facial analysesAmerican Journal of Medical Genetics Part A, 2011
- Illumina-microarray analysis of mycophenolic acid-induced cell death in an insulin-producing cell line and primary rat islet cells: New insights into apoptotic pathways involvedCellular Signalling, 2010
- An inosine 5′-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acidThe Pharmacogenomics Journal, 2009
- Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literatureAmerican Journal of Medical Genetics Part A, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant RecipientsClinical Pharmacokinetics, 2007
- Pregnancy Outcomes in Solid Organ Transplant Recipients With Exposure to Mycophenolate Mofetil or SirolimusTransplantation, 2006
- Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II geneJournal of Clinical Investigation, 2000
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205)Life Sciences, 1994
- Techniques for assessment of teratologic effects: embryo culture.Environmental Health Perspectives, 1976